Neuro-oncology — Specialty Profile

Exploratory, not prescriptive. This profile blends hard data (pay, match rates, burnout, demographics — each sourced and dated) with generalizations and synthesized online opinion about culture and "who fits." It's here to help you get curious and go find out for yourself — not to tell you who to become. Numbers marked ⟳ verify change every year; check the linked source before you quote one. Last reviewed: 2026-07-26.

Also called: Neuro-onc, cancer neurology. A 1–2 year fellowship entered after residency, not a residency you match into from medical school. Organ system: the nervous system, specifically tumors of the brain, spinal cord, and their coverings, plus the neurologic fallout of cancer and its treatment.

Multidisciplinary fellowship, entered after Neurology, Neurosurgery, Medical Oncology (Internal Medicine), Radiation Oncology, or Pediatrics.

The 30-second version

Neuro-oncology is the field that sits at the intersection of the brain and cancer, the subspecialty that takes ownership of tumors of the nervous system and the neurologic wreckage cancer leaves behind. A newly diagnosed glioblastoma, a brain full of metastases, a lymphoma seeding the spinal fluid, a checkpoint-inhibitor triggering autoimmune encephalitis: the neuro-oncologist diagnoses it, prescribes and manages the chemotherapy and targeted/immunotherapy, reads the surveillance MRIs for months or years, enrolls patients in clinical trials, and quarterbacks a multidisciplinary team of neurosurgeons and radiation oncologists. Its engine is longitudinal cognitive care, molecular tumor boards, and research, rather than the stopwatch of stroke or the procedures of the cath lab. The trade at the center of it: some of the deepest, most meaningful long-term relationships in medicine and a genuinely thrilling molecular and trial frontier, bought with one of the heaviest measured emotional loads anywhere in medicine, because so many of these tumors still kill, and you walk the same patient and family all the way there.

Quick dashboard (details and sources below)


Training after med school	6 years via the neurology route (PGY-1 intern year + 3 yr neurology + 2 yr fellowship)
Total from college start	~14 years (4 undergrad + 4 med school + 4 neurology residency + 2 fellowship)
Training chain	Med school (4) → PGY-1 intern year → 3 yr Neurology → 2 yr Neuro-oncology fellowship (neurology route; other entry doors run ~1 yr — see below)
Competitiveness (as a Neuro-oncology fellowship)	Low-to-moderate / niche — small, self-selecting, research-oriented applicant pool; limited public match data ⟳
Typical full-time pay	~$300,000–$400,000; recruiter average ~$341,000 — the highest of the neurology subspecialties AMN tracks ⟳
Pay vs. general neurology	AMN 2025 average ~$341,000 vs. general ~$244,000 (~+40%) — a real premium, tempered by academic concentration ⟳
Lifestyle	Light acute/overnight call; the load is emotional + academic/administrative, not a pager
Burnout	High and measured — ~61% of neuro-oncology physicians in the field's own survey ⟳
% women	No subspecialty figure — inherit neurology (33% practicing, 50.2% of residents) ⟳
DO / IMG accessibility	Reachable through the parent fields, which run 18.8% DO and 22.4% IMG (neurology) and 42.3% IMG (internal medicine) of filled PGY-1 positions; no fellowship-specific figure (limited data) ⟳

What they actually do

Neuro-oncologists diagnose and manage tumors of the nervous system and the neurologic complications of cancer and its treatment. The bread and butter is primary brain and spinal-cord tumors, meaning gliomas (including glioblastoma/GBM, the most common and most lethal adult primary brain tumor), meningiomas, medulloblastomas, and primary CNS lymphoma, plus metastatic disease that reaches the nervous system: brain metastases, leptomeningeal metastasis (cancer seeding the spinal fluid and meninges), and spinal cord/epidural compression. A large and growing part of the job is the neurologic fallout of cancer therapy: chemotherapy and radiation neurotoxicity, and increasingly the neurologic toxicities of immunotherapy (immune-checkpoint-inhibitor encephalitis and neuropathy, CAR-T neurotoxicity/ICANS), plus paraneoplastic neurologic syndromes (autoimmune neurologic disease triggered by a remote cancer).¹²

Crucially, the neuro-oncologist prescribes and manages the anti-tumor therapy themselves, from cytotoxic chemotherapy (the alkylator temozolomide is the backbone of glioma treatment) to targeted agents and immunotherapy, and runs the clinical-trial and molecular-tumor-board machinery that defines modern brain-tumor care. This is an inherently team specialty: the neuro-oncologist sits at the hub between neurosurgery (which resects the tumor), radiation oncology (which delivers the radiation), and neuropathology/molecular diagnostics (which classifies it). The signature skill is the longitudinal, high-stakes cognitive management of a cancer inside the nervous system rather than a procedure, including the hardest call in the field: reading a follow-up scan and deciding whether a growing spot is true tumor progression or "pseudoprogression"/treatment effect.¹³

Representative procedures and hands-on work (largely cognitive and pharmacologic rather than a cath-lab field): prescribing and managing systemic anti-tumor therapy (temozolomide, lomustine/PCV, bevacizumab, targeted agents like IDH inhibitors, immunotherapy) · serial MRI interpretation (progression vs. pseudoprogression/radionecrosis) · lumbar puncture with CSF cytology (leptomeningeal disease, CNS lymphoma) · intrathecal chemotherapy via LP or Ommaya reservoir · seizure, cerebral-edema, and steroid management · management of chemo/radiation/immunotherapy neurotoxicity · clinical-trial design and enrollment (an unusually central part of the job). They do not operate (neurosurgery) and do not deliver radiation (radiation oncology). They are the medical, coordinating quarterback.¹⁴

A day in the life (academic neuro-oncologist, the dominant setting): The morning is often a multidisciplinary brain-tumor or molecular tumor board, reviewing new MRIs, surgical pathology, and molecular markers with neurosurgery, radiation oncology, and neuropathology to set each patient's plan. Then outpatient clinic: a newly diagnosed GBM patient starting temozolomide plus radiation, follow-ups getting surveillance scans read for progression vs. treatment effect, patients being screened for and enrolled in clinical trials, symptom and steroid management, and hard goals-of-care conversations, since many of these tumors carry poor prognoses. Interspersed: inpatient consults (a new brain mass, leptomeningeal disease, immunotherapy neurotoxicity, cord compression), molecular sequencing results to interpret, and trial/protocol paperwork. It's cognitively dense, longitudinal, relationship-heavy, and emotionally weighty, closer to an oncologist's continuity rhythm than to acute stroke neurology.¹³

The training path & time to completion

Medical school (4 yrs) → PGY-1 intern year → 3 years of adult neurology (PGY-2–PGY-4) → 2-year UCNS-accredited Neuro-oncology fellowship → UCNS Certification in Neuro-Oncology.¹²³ That is the site's default neurology route. But neuro-oncology is one of the clearest multi-entry, non-ACGME subspecialties on the site, so get the structure right:

It's a fellowship, not a match-from-med-school residency. You first complete a full base residency, then add the neuro-oncology years on top.¹
Accreditation is UCNS, not ACGME. Neuro-oncology fellowships are accredited by the United Council for Neurologic Subspecialties (UCNS), the same body that accredits neurocritical care, behavioral neurology, and headache, rather than the ACGME. This is the single most important structural contrast with the sibling Vascular Neurology fellowship (which is ACGME-accredited with an ABPN board).⁵⁴
The board is UCNS Certification in Neuro-Oncology, and yes, a real certification exam exists, but it is not an ABMS/ABPN member board. It's the recognized credential for the field (given roughly biennially; ~46 new diplomates certified after the 2023 exam, ~342 diplomates nationally as of 2024, a genuinely small board), but it carries less regulatory weight than an ABMS board. It's not legally required to practice, but it is expected for academic neuro-oncology jobs.⁵ ⟳
Six prerequisite boards feed in. UCNS certification eligibility requires prior board certification in one of: Neurology; Child Neurology; Neurological Surgery; Internal Medicine + Medical Oncology; Pediatrics + Pediatric Hematology-Oncology; or Radiation Oncology, then a UCNS-accredited fellowship of 12+ months, with the application filed within 48 months of finishing. Alternative practice-track / academic-appointment / internationally-trained-faculty routes also exist (roughly 36 months of practice with ≥25% neuro-oncology plus supplementary qualifications), reflecting how young the field still is.²
Fellowship length differs by the door you came through. The UCNS regulatory floor is a uniform 12 months and does not vary by primary specialty. In practice the neurology route runs ~2 years (e.g., the Columbia/Weill Cornell program is an explicitly two-year design; MD Anderson lists 2–3 years), because a neurologist has to build the medical-oncology/chemotherapy fluency that a med-onc- or rad-onc-trained applicant already has. Oncology-trained entrants (medical oncology, radiation oncology) can often complete a ~1-year clinical fellowship; some practice neuro-oncology on their parent oncology board.⁴³⁶
Total from the start of college (neurology route): ~14 years (4 undergrad + 4 med school + 4 neurology residency + 2 fellowship), about one year longer than vascular neurology, because this fellowship is typically 2 years rather than 1.¹
Is the fellowship required? Not legally required to treat brain-tumor patients, but it is required for UCNS certification and is effectively required for the academic/NCI-cancer-center jobs where the field lives.⁵

How competitive is it?

As a fellowship, neuro-oncology is best described as niche and interest-limited rather than gatekept, and the honest headline is that public, NRMP-style match data does not exist for it. Unlike vascular neurology (which runs through the NRMP Specialties Matching Service and publishes granular fill tables), adult neuro-oncology is coordinated through the SF Match, sponsored by the Society for Neuro-Oncology (SNO), which does not publish the same fill-rate and applicant-to-position tables. So do not trust any single "fill %," because there isn't a credible published one.⁷

What can be said honestly:

~30 adult neuro-oncology fellowship programs participate in the SF Match, a prestigious roster (Johns Hopkins, Mayo, MSK, Duke, MD Anderson, UCSF, and peers). Many take a single fellow per year, so the national pipeline is on the order of a few dozen fellows annually. Limited data on exact positions and fill rate, so do not fabricate one.⁷ ⟳
The gate is interest, research pedigree, and academic intent rather than raw selectivity. This is a small field that self-selects for people willing to take on the emotional load and the academic or trial career, rather than "competitive" in the dermatology or neurosurgery sense of many applicants per slot. Strong research (often a PhD or dedicated research years) is common because the field is lab- and trial-heavy.⁷
Who enters: neurologists (the most common door) who want oncology plus longitudinal tumor care and clinical-trial work; medical oncologists sub-specializing into CNS tumors; neurosurgeons and radiation oncologists cross-training; and people aiming squarely at academic / NCI-cancer-center careers.¹⁷

Don't conflate it with Neurosurgical Oncology. That is a separate, surgery-side fellowship (CAST/SNS-accredited) for the person who physically resects the tumor; it only joined the NRMP Match in 2025. Neuro-oncology (UCNS) is the medical and cognitive manager of the tumor and its systemic and neurologic treatment, the same "who decides against who operates" split the vascular-neurology profile draws with neurointerventional.⁸

Board: UCNS Certification in Neuro-Oncology (a subspecialty credential, not an ABMS member board).⁵

Compensation — the robust version

Here is the fact that reframes the field against its neuro siblings: neuro-oncology sits toward the high end of neurology subspecialties on pay, the opposite of vascular neurology's roughly-flat premium. But the number comes with two honest caveats: the best available figure is recruiter data rather than a society survey, and the field is so academically concentrated that the setting discount claws some of the premium back. Always read these numbers against general neurology, because that's the comparison an extra one-to-two fellowship years is competing with.

Primary benchmark, the AMN Healthcare Neurologist Salary Report 2025:⁹ ⟳

Neuro-oncology average ≈ $341,000 (starting ≈ $230,000), reported as the highest-earning neurology subspecialty in AMN's set.
Within the same report: General Neurology ≈ $244,000 (starting ≈ $200,000) · Multiple Sclerosis ≈ $267,000 · Neuro-Critical Care ≈ $270,000 · Movement Disorders ≈ $240,000 · Pediatric Neurology ≈ $225,000–$250,000.
So the premium over general neurology is roughly +$97,000 (~+40%) on the AMN numbers, a large, real premium rather than the ~2% of vascular neurology.

But read the survey universe honestly. AMN is recruiter/placement data. The society survey the sibling profiles lean on, AAN 2025 Neurology Compensation and Productivity, does not break out "neuro-oncology" as a discrete line, and its general neurology baseline (~$309,882 total comp) is higher than AMN's $244,000 because it measures practicing-member total comp rather than recruiter starting/placement figures.¹⁰ So the AMN $341k and the AAN general baseline live in different universes, and you should not directly subtract one from the other. The defensible statement: recruiter data puts neuro-oncology at the top of the neurology subspecialties it tracks and well above its own general-neurology figure; the society survey doesn't isolate it, so treat the exact premium as directional. A plausible full-time band is ~$300,000–$400,000. ⟳

Why there's a premium at all, and why it's not a procedural windfall. Neuro-oncology's economic engine is oncology-style rather than neurology-style: it's not a Botox, DBS, EMG, or cath-lab field. Value is generated through chemotherapy/infusion and drug-administration management, complex cognitive (E/M) billing, and clinical-trial funding or NCI grant support, the med-onc-adjacent reimbursement environment rather than a signature high-margin procedure (surgery belongs to neurosurgery, radiation to radiation oncology).¹⁹

The setting caveat that partly offsets it. Neuro-oncology is overwhelmingly academic and NCI-cancer-center based, because that's where the tumor volume, the trials, and the tumor boards are. And in neurology, academic settings pay less than hospital/private (AAN 2025 medians: academic ~$277,288 against hospital-based ~$362,500).¹⁰ Because so many neuro-oncologists are academic faculty, real take-home for the modal job likely sits below what a flat recruiter average implies, traded for research protected time, trial funding, and cancer-center compensation structures. Frame it honestly: higher-end for a cognitive neurology subspecialty, but concentrated in academic centers where the setting discount eats into the premium. ⟳¹⁰

Aggregators: disregard them for a point estimate. ZipRecruiter, Comparably, and Marit Health list "neuro-oncologist" averages spanning roughly ~$260k to ~$440k depending on how they pool titles; they mix academic, part-time, and mixed roles and are unreliable, the same disclaimer the vascular profile applies. Use AMN's ~$341k as the central figure and the ~$300k–$400k band as the spread.¹¹ ⟳

Geography: no neuro-oncology-specific table exists (limited data). Inherit the neurology signal, but with a twist. Because the jobs are tethered to academic cancer centers (Boston, New York, Houston/MD Anderson, Durham, San Francisco), the usual "rural pays a premium" neurology dynamic is weaker here. You largely go where the cancer center is rather than where the pay is highest.¹ ⟳

Lifestyle

The defining lifestyle fact of neuro-oncology is a near-inversion of its acute neuro siblings: the clock is genuinely controllable, since there is no "code stroke" stopwatch, but the emotional, academic, and administrative load is heavy. More than the hours, it's what the work asks of you after hours that bends the week.

Hours sit broadly in the neurology band, roughly 45–55 clinical hours/week for a clinical-heavy neuro-oncologist, but the mix is different from general neurology: a large chunk is outpatient tumor clinic (new diagnoses, chemo/targeted-therapy management, surveillance-MRI review, survivorship and end-of-life conversations), molecular/multidisciplinary tumor boards, inpatient cancer-service consults, and, for the academic majority, protected research and clinical-trial time.¹¹²

Call burden is the key contrast with the acute neuro subspecialties. Neuro-oncology has light acute/overnight call relative to vascular neurology, neurocritical care, or neurointerventional. There is no thrombolysis clock. Inpatient consult and cancer-service coverage exist, but the defining after-hours reality is being emotionally reachable to dying patients and frightened families, plus the cognitive tail of managing acutely deteriorating tumor patients (seizures, herniation, immunotherapy neurotoxicity). Where the parent profile says "acute stroke call is THE variable," here the acute-overnight variable is low and the emotional-continuity variable is high.¹²

What actually erodes schedule control (and it isn't a pager): (1) research, grant, and trial obligations that expand to fill evenings and weekends, the academic treadmill; (2) documentation and prior authorization for expensive oncology drugs and trial enrollment; and (3) emotional labor that doesn't clock out, because you carry patients home. Continuity is double-edged: you build years-long relationships, but many end in death, and you hold that thread. The field's own burnout survey quantified the point, at ~4.5× higher burnout for those doing ≥10 hrs/week of at-home work and ~4× for >10 hrs/week of administrative work. The "hours" that hurt here are evening charting and trial admin rather than overnight call.¹²

Lifestyle rating: 3/5. The same headline number as parent neurology, for the opposite reason from stroke. The clock is more controllable than most of neurology (few overnight emergencies, no stopwatch); what pulls it back to a 3 is the academic-research workload and the emotional/administrative carry. If you want a purely 9-to-5, low-emotional-residue job, this isn't it; if you want daytime-predictable work without a pager ruling your nights, it delivers that.

Wellbeing — the part to take seriously

This is the section that matters most for this field, and, unusually for a subspecialty, there is specific, named, measured data rather than just inherited parent numbers.

Burnout is high, and it's documented. The landmark source is the SNO/EANO burnout survey (Neuro-Oncology, 2020; data collected 2016–17; n≈345 SNO + 121 EANO):¹²¹³

~61–63% high burnout overall (SNO 63%, EANO 60%); physicians specifically ~61% (SNO) / ~65% (EANO). ⟳
Components (SNO): high emotional exhaustion 48%, high depersonalization 36%, low personal accomplishment 28%.
Non-physician team members ran even higher. Basic scientists ~83%, allied health ~68%, a whole-team stressor rather than just doctors.
Lifestyle markers were poor: ~58% slept <7 hrs/night; only ~49% spent regular time with family/friends.
Underestimation: among those who reported no burnout, ~35% actually met MBI criteria, so people don't realize how depleted they are.

Read that against the reference data: parent neurology ~44% (Medscape 2024; field-synthesis ~48–55%) and oncology ~53% (Medscape 2024, among the highest base specialties).¹⁴ Neuro-oncology sits at the intersection of two already-high-burnout parents, and the subspecialty-specific survey lands at the high end (~61%), among the higher figures anywhere in medicine, driven by emotional exhaustion, at-home/administrative workload, and the relentlessness of poor-prognosis disease. ⟳

But the paradox that defines the field: high burnout with high satisfaction. The same survey found a median career and job satisfaction of 7/10 and, critically, that career satisfaction was the strongest protective factor against burnout.¹²¹⁵ People are exhausted and find the work deeply meaningful. It maps onto the parent-oncology pattern, where oncology posts high burnout alongside a long-standing reputation for people staying in it. This page used to put a number on that, both for oncology's would-choose-again rate and for an overall physician anchor of ~78%. Both are gone. Nobody publishes a would-choose-again figure by specialty and nobody has since about 2019, and there is no current overall figure either, so none is given here.¹⁴ The honest read is that retention here is driven by meaning rather than comfort.

Happiness outside work. No neuro-oncology-specific figure exists, so inherit the two parents, both among the least happy outside work at neurology ~54% and oncology ~51% (Medscape 2024), and add the specific tax of carrying dying patients home.¹⁴ ⟳

Emotional load is the single most important thing a premed should understand about this field.

The weight is real and sustained. Many primary brain tumors, glioblastoma above all, carry poor prognoses measured in months to a couple of years. You diagnose, treat, build a relationship over surveillance scans, and frequently walk the same patient and family all the way to the end. Neuro-oncology also sits at a cruel intersection: the tumor (or its treatment) often erodes cognition and personality, so families grieve the person while the person is still alive. Community sentiment bluntly calls it "the most depressing field," a caricature, but one pointing at something true.¹⁶
The counterweight is equally real, and it's why people stay. Deep, longitudinal relationships; the intellectual pull of a fast-moving molecular/trial landscape (you're often the patient's route to a cutting-edge therapy); genuine wins (meningiomas, some low-grade gliomas, CNS lymphoma and germinoma responders, long survivors); and the meaning of being fully present at the hardest moment of a person's life. The "perpetually burning flame" editorial frames it exactly this way: the intensity and lifelong continuity that cause the burnout are the same things that make it sustaining when career satisfaction is protected.¹⁵

Career longevity is mixed, and it hinges on emotional sustainability rather than the body. Physically it's low-demand, outpatient and cognitive, and telehealth-friendly for a later-career wind-down, sustainable for decades like the rest of neurology. The limiter is compassion fatigue and cumulative grief rather than circadian call. Notably, the survey found the lowest burnout in the ≥55 age group (~51%), consistent with a field where those who stay long-term have found their equilibrium, and where the acute-call attrition that shortens EM and stroke careers simply doesn't apply. The named protective moves: institutional wellness programs, palliative-care skill-building, protected research meaning, and guarding family and exercise time.¹²¹⁵

Who's in the field (demographics)

Fellowship-specific demographic breakdowns are essentially unavailable; limited data. SF Match and UCNS don't publish NRMP-style composition tables for neuro-oncology, so parent-field reference data and honest gaps are the best available.

Women: no published neuro-oncology-specific figure (limited data). Inherit parent neurology: 33% of practicing neurologists (AAMC, 2022 data) and 50.2% of neurology residents (ACGME, AY2024-25). The two count different generations, and the seventeen-point spread between them is the pipeline turning over rather than a disagreement. Because neuro-oncology also draws from oncology (medical oncology skews closer to gender parity) and is academic, the field may run modestly higher than 33%, but no reliable subspecialty percentage exists, so this is not asserted.¹⁴ ⟳
DO: no neuro-oncology-specific figure (limited data). Parent neurology gave 18.8% of its filled PGY-1 positions to DO graduates in 2026, a little under the 21.5% across all PGY-1 positions, and about 12% of vascular-neurology fellows are DOs. Research-heavy academic fellowships tend to skew MD/MD-PhD, so the DO share here is plausibly lower than in general neurology, but that's inference rather than a measured number.¹⁴ ⟳
IMG: no neuro-oncology-specific figure (limited data). Parent neurology gave 22.4% of its filled PGY-1 positions to international graduates, against 25.2% across all PGY-1 positions, and the vascular sibling saw ~38% IMG at fellowship level. Neuro-oncology's academic/research selectivity may make it somewhat less IMG-heavy than a shortage subspecialty like vascular. Again, that is inference, so cite the parent and flag the gap.¹⁴ ⟳
URiM: no neuro-oncology-specific data (limited data). Parent neurology is cited as having below-average URiM representation (Black and Hispanic/Latino physicians underrepresented relative to the US population), per AAMC workforce data and AAN diversity initiatives.¹⁴ ⟳

Culture, personality & the online stereotypes

Who gravitates here: neurologists (and oncologists, neurosurgeons, radiation oncologists) drawn to the intersection of the brain and cancer, people pulled by hard molecular science, clinical trials, and translational research, who also have the emotional constitution to hold long relationships with dying patients. Online, the read is that this is a cerebral, academic, research-forward crowd: the field lives at NCI-designated cancer centers, so "who's here" skews toward people who want a foot in the lab or in trial design rather than high-volume community practice. Many are mission-driven, since glioblastoma is one of medicine's great unsolved problems and people come to push the frontier on it. And it takes a particular temperament: comfortable with poor odds, motivated by incremental progress and presence rather than cures, steady under sustained grief. As always, plenty of people in the field don't fit any single mold.

The stereotypes. Community perception rather than fact. Each carries a kernel and an unfair edge, and plenty of people do not fit the mold:

"The academic saints, the ones who can handle the sad stuff." The read online is that neuro-oncologists are the emotionally durable, mission-driven academics who chose one of the heaviest patient populations in medicine on purpose. Kernel of truth: the emotional constitution is real and self-selected. Unfair edge: the halo. They'd be the first to say they're not saints, just people who found the work meaningful and learned to protect themselves.
"The most depressing specialty." A blunt community label pinned to the glioblastoma prognosis. Kernel: the mortality is genuinely high. Unfair edge: it erases the real wins (meningioma, low-grade glioma, CNS lymphoma, long survivors), the trial-driven optimism, and the fact that presence-at-the-end is meaningful work, not just grim work.
"Lab coat over stethoscope, more scientist than clinician." The perception that it's a research career with patients attached, dominated by trial PIs and molecular-tumor-board thinkers. Kernel: it is unusually academic and research-heavy. Unfair edge: the clinical relationships are the emotional core of the job, and community-leaning neuro-oncologists do exist.
"Do you even change the outcome?" A pointed jab in trainee discussion that neuro-oncologists "mostly manage seizures and headaches" while neurosurgery and radiation oncology do the definitive work and medical oncology could cover the chemo. It's a real, live intramural debate, sharper in community settings and much less true in academic or trial practice, where the neuro-oncologist quarterbacks systemic therapy, trial enrollment, and the whole multidisciplinary plan.¹⁶

What people say online (synthesized and paraphrased, not quotes): Across trainee and physician forums, the loudest theme is a candid reckoning with the emotional weight. People call it beautiful and brutal in the same breath, warn that you must be sure you can carry poor-prognosis patients for years, and note it's not for anyone who needs the dopamine of frequent cures. Close behind is a job-market caution: the field is heavily academic and geographically concentrated in big centers (Boston, New York, MD Anderson-tier institutions), with thin private-practice demand and, some argue, more fellowship output than mid-size markets can absorb, so if you want to live anywhere, ask hard questions early. There's a genuine scope-of-practice debate (see the stereotype above) about how much value the neuro-oncologist adds outside academics. And there's real cautious optimism about the science, covering immunotherapy, CAR-T for CNS disease, targeted therapy by molecular subtype, and trials, tempered by hard honesty that glioblastoma outcomes remain mostly palliative for now. Overall tone: proud of the mission and the science, clear-eyed about the grief and the narrow job geography, and united that you do this because it means something rather than because it's easy or lucrative.¹⁶

Voices from the field. Paraphrased from public writing, with links to the originals:

The SNO/EANO burnout survey (Neuro-Oncology, 2020). The field's own members measured ~61–63% high burnout alongside a median 7/10 career satisfaction, showed career satisfaction to be the strongest protector, and named at-home and administrative workload as the biggest modifiable drivers.¹²
Dunbar EM & Kumthekar PU, "In pursuit of a perpetually burning flame: preventing burnout in neuro-oncology" (Neuro-Oncology editorial, 2020) argues the intensity and lifelong continuity of caring for brain-tumor patients both drives burnout and, when meaning is protected, sustains resilience; recommends personal, professional, and societal interventions.¹⁵
The Society for Neuro-Oncology (SNO) frames the field around multidisciplinary, trial-driven progress against tumors like glioblastoma, the mission-and-science identity the community rallies around.¹⁷
The Student Doctor Network community repeatedly stress-tests "should I do neuro-oncology?" and lands on a nuanced answer of emotionally demanding, academically concentrated, thin private-practice market, and real scope-of-practice debate, while acknowledging that the meaning and the science draw the right people powerfully.¹⁶

Why people choose it / why people leave

Why choose it: you work at the frontier of one of medicine's hardest problems (glioblastoma), with a fast-moving molecular/immunotherapy/trial landscape that makes every year different · deep, meaningful, longitudinal relationships with patients and families · a genuinely intellectual, academic, research-rich career (molecular tumor boards, trial design, translational science) · higher-end neurology-subspecialty pay (~$341k, AMN 2025) · light acute/overnight call relative to stroke or neurocritical care · concentration at prestigious NCI cancer centers with strong colleagues and resources · the meaning of being fully present for people at the hardest moment of their lives.

Why leave or avoid it: the emotional load is real, sustained, and measured (~61% physician burnout in the field's own survey), with poor prognoses, cognitive and personality decline in patients, and repeated grief · high risk of compassion fatigue if meaning and wellness aren't actively protected · a heavy academic-research and administrative/at-home workload (the biggest modifiable burnout driver) · a narrow, academic, geographically concentrated job market, so it is hard to practice just anywhere · an intramural scope-of-practice debate about value outside academics · pay that's good for neurology but not procedural-windfall money, for an extra one-to-two fellowship years · glioblastoma outcomes that remain mostly palliative despite the science.

Best fit if: you're pulled by the brain-cancer intersection and by trials/translational research · you have (or can build) the emotional constitution to carry poor-prognosis patients for years and stay whole · you find meaning in presence and incremental progress, not just cures · you want an academic, cancer-center career and are okay living where those jobs are · you want intellectual depth without a stopwatch/overnight-call lifestyle · you'll deliberately protect family, exercise, and non-work outlets (the data say this is what keeps people afloat).

Not for you if: frequent patient death and cognitive decline would grind you down · you need the dopamine of cures and quick wins · you want broad geographic freedom or a robust private-practice market · you want procedural income or a fast financial payoff for the extra years · you'd resent a research/administrative workload spilling into evenings · you want a purely transactional, low-emotional-residue job.

The FLI angle — Neuro-oncology for first-gen, low-income & immigrant students

Where it fits FLI realities well:

Reachable through the parent fields. About 41% of neurology's PGY-1 positions went to DO and international graduates in 2026, close to the 46.7% those two groups took across all PGY-1 positions, so the neurology door is ordinary in width rather than unusually wide. The internal-medicine door is genuinely wide, at 42.3% IMG of its 10,657 filled positions. And neuro-oncology fellowships are not among the ultra-competitive ones, since the applicant pool is small and self-selecting for people willing to take on the emotional load. For a DO or IMG neurology grad who genuinely wants this, it's a realistic reach rather than a long shot, and the medical-oncology route in is wider still.¹⁴
Higher-end neurology-subspecialty pay. At ~$341k (AMN 2025), it's the top of AMN's neurology-subspecialty set, a real income for someone carrying large training debt, and better than most cognitive neuro subspecialties.⁹
PSLF fits naturally, arguably better than in almost any field. Neuro-oncology lives almost entirely at academic medical centers and NCI-designated cancer centers, which are overwhelmingly 501(c)(3) nonprofit and university employers, exactly the qualifying employers for Public Service Loan Forgiveness. Because the jobs cluster in nonprofit academia, 10 years of qualifying payments toward forgiveness is very achievable here. (Ground it honestly: most physicians carry ~$200k+ in student debt; PSLF is a real but paperwork-heavy lever rather than a guarantee, and this path is one-to-two extra fellowship years before attending pay.)
Prestige-center access is a leveler. These are exactly the brand-name institutions a first-gen student can feel locked out of, and the neuro-oncology door into them is genuinely open through the parent-field pipeline plus a small fellowship pool.

Risks to name honestly:

The job market is narrow and geographically concentrated, the biggest FLI risk here. Neuro-oncology jobs cluster at large academic cancer centers in major metros (Boston, New York, Houston-tier). If family, immigration status, or dependents tie you to a particular place, especially a mid-size or lower-cost market, the jobs may simply not be where you need to live. The community flags this repeatedly. Ask, before you commit: where can I actually get a job with this?¹⁶
Extra years before attending pay. The neurology route is a 2-year fellowship on top of a full residency, meaning two more years of trainee income before the higher salary starts. For someone who needs to start earning and paying down debt fast, that delay is a real trade-off, softened only partly by the higher end-salary and strong PSLF fit.
The emotional cost isn't free. The measured ~61% burnout and heavy grief load are a genuine, sustained tax, easy to underestimate from the outside, and a real risk if you're also carrying financial and family pressure with thin support networks. The data are blunt: protecting family time, exercise, and outlets is what keeps people whole, so build that in from day one.¹²
Not a fast financial upgrade. Good pay for neurology, but not procedural money, and it costs extra years. Choose it for the mission and the science, not as a quick return on investment.

Bottom line: neuro-oncology is a reachable, prestige-center, PSLF-friendly path for DO/IMG and first-gen neurology (or oncology) grads who are genuinely called to the brain-cancer frontier, with higher-end neurology-subspecialty pay and light overnight call. But be clear-eyed: the job market is narrow and clustered in big academic metros, it costs extra fellowship years before attending pay, and it carries one of the heaviest measured emotional loads in medicine. Choose it because the meaning and the science pull you, and because you know you can carry the grief, rather than as a geographic-freedom or fast-money play. Shadow an outpatient neuro-oncology clinic, sit in on a molecular tumor board and an end-of-life conversation, and ask any prospective program where its graduates actually found jobs, before you commit.

Fun facts

Neuro-oncology is a UCNS-certified subspecialty rather than an ABMS/ABPN board, one of the clearest examples on the site of a recognized field whose credential sits outside the traditional member-board system.
It is genuinely a six-door field: neurology, child neurology, neurosurgery, medical oncology, radiation oncology, and pediatrics can all lead to the same UCNS certification, a rare shared-border specialty.²
It's a small board, with only a few hundred certified diplomates nationally (~342 as of 2024), reflecting how niche and how young the field is.⁵
The brain-tumor diagnosis went molecular: under the WHO 2021 CNS tumor classification, markers like IDH mutation, 1p/19q codeletion, and MGMT promoter methylation now define tumor types that used to be named by how they looked under the microscope.¹⁸
Temozolomide, an oral alkylating chemotherapy, is the workhorse of glioma treatment, and the modern frontier includes IDH inhibitors (e.g., vorasidenib) for certain low-grade gliomas, a targeted-therapy story that barely existed a decade ago.¹⁸
The person who decides and manages the tumor's medical treatment and the person who operates on it are usually two different subspecialists, the neuro-oncologist and the neurosurgical oncologist, the same "who decides against who operates" split that trips people up in stroke care.⁸
The field's defining paradox, straight from its own data: among the highest burnout in medicine (~61%) coexisting with a 7/10 median career satisfaction, so people are exhausted and find the work profoundly meaningful at the same time.¹²

Sources

Training path, six prerequisite entry routes, the medical-vs-surgical distinction, scope of practice (primary CNS tumors, metastases, neurologic complications of cancer, paraneoplastic syndromes), and revenue-driver structure (oncology-style chemo/infusion + clinical trials, no signature procedure). Road to MD research synthesis, kept consistent with the neurology profile on this site; UCNS and program primary sources below. 2026. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹
UCNS — Neuro-oncology Examination Eligibility Criteria (updated 12/15/2025): qualifying prior certifications = Neurology; Child Neurology; Neurological Surgery; Internal Medicine + Medical Oncology; Pediatrics + Pediatric Hematology-Oncology; or Radiation Oncology; UCNS-accredited fellowship of "12 or more months"; apply within 48 months of completion; also practice-track/academic-appointment/internationally-trained-faculty routes (~36 months with ≥25% neuro-oncology plus supplementary qualifications). https://www.ucns.org/common/Uploaded%20files/Certification/Neuro-oncology%20Examination%20Eligibility%20Criteria.pdf (2025). ↩ ↩² ↩³ ↩⁴
Columbia University (with Weill Cornell) Neuro-Oncology Fellowship — a two-year training program divided between the two institutions (a 1-year option "in rare cases"), fulfilling UCNS training criteria; describes tumor boards, outpatient + inpatient work, and collaboration with neurosurgery, radiation oncology, neuropathology, palliative care, and medical/pediatric oncology. https://www.neurology.columbia.edu/education/fellowship-programs/neuro-oncology-fellowship-training-program (accessed 2026). ↩ ↩² ↩³ ↩⁴
UCNS — Neuro-oncology Program Requirements (approved 2021-02-10): fellowship "no less than 12 [months]"; ≥80% of fellow time in supervised neuro-oncology practice; combined clinical/research fellowships may extend to 36–48 months; no specialty-specific duration variation in the regulation itself. https://www.ucns.org/common/Uploaded%20files/Accreditation/Program%20Requirements/NO%20Program%20Requirements%20APPROVED%2020210210.pdf (2021). ↩ ↩² ↩³
United Council for Neurologic Subspecialties (UCNS) — Neuro-Oncology Certification: UCNS-accredited (not ACGME); a real certification examination (given ~biennially); ~46 new diplomates after the 2023 exam and ~342 diplomates nationally as of 2024; UCNS credential is not an ABMS/ABPN member board. UCNS Neuro-oncology Certification page https://www.ucns.org/Online/Online/Certification/Neuro-oncology_Cert.aspx ; AAN/UCNS news, "UCNS Accredits Programs, Certifies New Diplomates…" https://www.aan.com/news/ucns-accredits-programs-and-certifies-new-diplomats (2024). ⟳ ↩ ↩² ↩³ ↩⁴ ↩⁵
UT MD Anderson Cancer Center — Neuro-Oncology Fellowship (GME): 2–3 years (year 1 clinical, year 2 clinical + research, optional protected research year); entry from adult neurology or neurosurgery; UCNS neuro-oncology certification eligibility; multidisciplinary work across neurosurgery, radiation oncology, neuropathology, and neuroradiology. https://www.mdanderson.org/education-training/clinical-training/graduate-medical-education/residencies-fellowships/neuro-oncology.html (accessed 2026). ↩
Society for Neuro-Oncology (SNO) Adult Fellowship Match and the SF Match — ~30 participating adult neuro-oncology fellowship programs; no NRMP-style published fill-rate/applicant-to-position tables (limited data — do not fabricate a fill %). SNO Adult Fellowship Resources https://www.soc-neuro-onc.org/about/adult-fellowship-resources, which states that SNO sponsors the match, that San Francisco Match conducts it, and that participating programs are listed only to registered candidates; SF Match Neuro-Oncology overview https://www.sfmatch.org/specialty/neuro__oncology-fellowship (2024–26). ⟳ ↩ ↩² ↩³ ↩⁴
NRMP, "Neuroendovascular Intervention and Neurosurgical Oncology Fellowship Programs Join the Match" — Neurosurgical Oncology is a separate, surgery-side (CAST/SNS) fellowship that joined the NRMP Match in 2025; distinct from the UCNS medical neuro-oncology credential. https://www.nrmp.org/about/news/2025/12/neuroendovascular-intervention-and-neurosurgical-oncology-fellowship-programs-join-the-match/ (2025). ↩ ↩²
AMN Healthcare — Neurologist Salary Report 2025 — subspecialty averages: Neuro-Oncology ~$341,000 (highest in AMN's neurology-subspecialty set; starting ~$230,000), General Neurology ~$244,000 (starting ~$200,000), Multiple Sclerosis ~$267,000, Neuro-Critical Care ~$270,000, Movement Disorders ~$240,000, Pediatric Neurology ~$225,000–$250,000. https://www.amnhealthcare.com/blog/physician/perm/neurologist-salary-report-2025/ (2025). ⟳ ↩ ↩² ↩³
AAN 2025 Neurology Compensation & Productivity survey (2024 data) — does not break out neuro-oncology as a discrete line; General Neurology median total comp ~$309,882; by setting, hospital-based ~$362,500 vs. academic medical center ~$277,288 (the academic-vs-hospital gap that partly offsets neuro-oncology's subspecialty premium). Carried on the neurology and vascular neurology profiles on this site, which are cross-references; the source is the AAN executive summary https://www.aan.com/siteassets/home-page/tools-and-resources/practicing-neurologist--administrators/benchmarking-data/neurology-compensation--productivity/25-ncp-executive-summary.pdf (2025). ⟳ ↩ ↩² ↩³
Crowdsourced aggregator "neuro-oncologist" salary figures (~$260k–$440k range; pooling academic, part-time, and mixed roles — unreliable for a point estimate; use as spread illustration only). ZipRecruiter https://www.ziprecruiter.com/Salaries/Neuro-Oncologist-Salary ; Comparably https://www.comparably.com/salaries/salaries-for-neuro-oncologist ; Marit Health https://www.marithealth.com/o/-/neuro-oncologist-neurology/salary (2025–26). ⟳ On Marit Health: it publishes a panel of self-reported physician salaries, and displays MGMA and AMGA benchmarks beside them that are masked unless you create an account. The figure quoted here comes from the self-reported panel, not from either benchmark. Read it as crowd data: unweighted, of unstated sample size, and directional. ↩
SNO/EANO burnout survey — "Burnout and career satisfaction in neuro-oncology: a survey of the Society for Neuro-Oncology and the European Association of Neuro-Oncology memberships," Neuro-Oncology (2020); n≈345 SNO + 121 EANO (2016–17 data): ~61–63% high burnout overall, physicians ~61% (SNO)/~65% (EANO); high emotional exhaustion 48%, depersonalization 36%, low personal accomplishment 28% (SNO); median career/job satisfaction 7/10 with career satisfaction the strongest protector; ≥10 hrs/week at-home work ~4.5× and >10 hrs/week administrative work ~4× burnout risk; ~58% sleep <7 hrs/night; ~35% of "no burnout" self-reporters met MBI criteria; lowest burnout in the ≥55 age group (~51%). https://pmc.ncbi.nlm.nih.gov/articles/PMC7283020/ ; https://pubmed.ncbi.nlm.nih.gov/31832657/ (2020). ⟳ ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹
CancerNetwork — coverage of the SNO/EANO burnout survey (corroborates ~61–63% burnout, high emotional exhaustion, and the protective effect of career satisfaction). https://www.cancernetwork.com/view/investigating-burnout-and-career-satisfaction-among-neuro-oncologists (2020). ↩
Cross-specialty figures. Neurology 33% women in practice: AAMC, "Women are changing the face of medicine in America" (2022 data), https://www.aamc.org/news/women-are-changing-face-medicine-america. Women in training: ACGME, Data Resource Book, Academic Year 2024-2025, Table C.21, https://www.acgme.org/globalassets/pfassets/publicationsbooks/2024-2025_acgme_databook_document.pdf, which puts neurology residents at 50.2% women in academic year 2024-25. Correction 2026-08-13: this page previously carried ~40% of neurology residents, in the Quick dashboard and in Who's in the field. That table covers ACGME-accredited programs and so carries no neuro-oncology row, the fellowship being UCNS-certified, which is why the subspecialty gap named above is real. Burnout, neurology 44% and oncology 53% against an all-physician average of 49%, with field-synthesis reporting often placing neurology higher at ~48–55%: Medscape Physician Burnout & Depression Report 2024, n=9,226, fielded July–October 2023, paywalled and returning HTTP 402, so it reaches this page through three independent relays that agree on the edition, the instrument and every row — Healthgrades Pro (https://resources.healthgrades.com/pro/the-most-and-least-burned-out-physicians-by-specialty) and Advisory Board (https://www.advisory.com/daily-briefing/2024/01/31/physician-burnout). DO and IMG shares: NRMP, Results and Data: 2026 Main Residency Match, May 2026, Table 2, https://www.nrmp.org/wp-content/uploads/2026/05/Main_Match_Results_and_Data-2026.pdf — neurology offered 1,003 PGY-1 positions and filled 999, taking 583 US MD seniors, 4 MD graduates, 181 DO seniors, 7 DO graduates, 49 US IMGs and 175 non-US IMGs, so 18.8% DO (188 of 999) and 22.4% IMG (224 of 999) on the positions-filled denominator. The same table's all-PGY-1 totals row gives 21.5% DO and 25.2% IMG of 38,354 filled positions, and 46.7% for the two groups together; it also confirms internal medicine as the largest IMG entry point, at 4,508 of its 10,657 filled positions (42.3%). Swept 2026-08-17: the demographics section carried ~16.5% DO from the 2025 report and called neurology "IMG-friendly" and "one of the more IMG-accessible specialties" without a figure. The 2025 pair the family inherited was internally inconsistent as well as a cycle old — 16.5% was DO seniors alone over positions offered (154 of 932) while the ~29% quoted elsewhere counted both IMG types. On one denominator the two cycles read DO 17.0% → 18.8% and IMG 29.1% → 22.4%. The FLI section's "one of the more DO- and IMG-accessible specialties" and its "nearly half" went with the number: the real figure is about 41%, slightly below the all-class 46.7%. The internal-medicine share was also stated against 11,194, which is positions offered rather than filled; it is now on the filled denominator like the rest. Value swept: 18.8% DO and 22.4% IMG, denominator positions filled, source NRMP Main Match 2026 Table 2. The "happiness outside work" figures, neurology ~54% and oncology ~51%, come from a Medscape 2024 lifestyle table reported second-hand by HCN, which does not link the table it is reporting and which nobody here has opened. Unverified — do not treat as confirmed. No URL is given for it, because pointing a reader at a secondary that cannot show its own source would look like verification and would not be any. Would-choose-again is deleted rather than corrected: the ~78% that used to sit here has no current publisher, by specialty or overall, and nothing replaces it. On URiM, no current race-and-ethnicity-by-specialty table is published anywhere, and AAMC's 2025 Key Findings gives the aggregate only (5.3% Black or African American, 6.7% Hispanic or Latino of active physicians in 2024, https://www.aamc.org/data-reports/data/2025-key-findings), so the "below-average" line is a directional read rather than a cited figure. ⟳ ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸
Dunbar EM & Kumthekar PU, "In pursuit of a perpetually burning flame: preventing burnout in neuro-oncology," Neuro-Oncology editorial (2020) — the intensity and lifelong continuity of brain-tumor care both drive and (via protected career satisfaction) protect against burnout; recommends personal, professional, and societal interventions. https://academic.oup.com/neuro-oncology/article/22/6/750/5813709 ; https://pmc.ncbi.nlm.nih.gov/articles/PMC7283029/ (2020). ↩ ↩² ↩³ ↩⁴
Student Doctor Network — "Perspectives on neuro-oncology field / need advice" thread (paraphrased community sentiment): emotional weight of poor-prognosis brain tumors ("most depressing field"); narrow, academic, geographically concentrated job market (big centers; thin private practice; possible fellowship oversupply for mid-size markets); scope-of-practice debate (community neuro-oncology "mostly seizures/headaches" vs. academic quarterbacking of systemic therapy and trials); cautious optimism on immuno/targeted therapies and trials; entry primarily via neurology. https://forums.studentdoctor.net/threads/prospectives-on-neuro-oncology-field-need-advice.1397189/ (accessed 2026). ↩ ↩² ↩³ ↩⁴ ↩⁵
The Society for Neuro-Oncology (SNO) — mission and identity framing around multidisciplinary, trial-driven progress against CNS tumors such as glioblastoma. https://www.soc-neuro-onc.org (accessed 2026). ↩
WHO Classification of Tumors of the Central Nervous System, 5th edition (2021) — molecular markers (IDH mutation, 1p/19q codeletion, MGMT promoter methylation) now integral to CNS tumor diagnosis; temozolomide as the alkylator backbone of glioma therapy and IDH inhibitors (e.g., vorasidenib) as a modern targeted-therapy advance for certain low-grade gliomas. Louis DN et al., Neuro-Oncology 2021;23(8):1231–1251, https://pmc.ncbi.nlm.nih.gov/articles/PMC8328013/ (2021). ⟳ ↩ ↩²

Researched with AI assistance and reviewed by hand. How this site is made